Targets › DSG3
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Jan 2029.
A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion. Required for adherens and desmosome junction assembly in response to mechanical force in keratinocytes. (UniProt, P32926)
Open in Phaseline: the race on DSG3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cabaletta Bio | DSG3-CAART Desmoglein 3 chimeric autoantibody receptor T cells | DSG3 | Phase 1 | Pemphigus Vulgaris | Jan 2029 |
Pemphigus Vulgaris (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.